Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
Bristol Myers Squibb (BMY) closed the most recent trading day at $52.41, moving +2.36% from the previous trading session.
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript
Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript
5 Blue Chip Stocks to Buy Now That Pay Reliable 4%+ Dividends
Investors love high-yield dividend stocks, especially the blue chip variety, because they offer a significant income stream and have massive total return potential.
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.
Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
BMY Gains on News of Continuation of Alzheimer's Disease Study
Bristol Myers jumps after choosing to continue its phase III ADEPT-2 study on Cobenfy for Alzheimer-related psychosis, delaying data to next year.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Bristol Myers Squibb Stock Climbs on Alzheimer's Trial Update. What to Know.
The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer's disease.
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules
A U.S. judge on Monday rejected Bristol Myers Squibb's bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
